Argentina Gastric Cancer Treatment Market is expected to grow with the CAGR of 9.6% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/reports/argentina-gastric-cancer-treatment-market
Argentina gastric cancer treatment market is a highly consolidated market. The market has witnessed increased strategic developments owing to favorable market scenario.
The major players dealing in Argentina gastric cancer treatment market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.
For instance,
- In November 2019, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan N.V. and formed a new company named Viatris. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market
Genentech, Inc. is dominating player in Argentina gastric cancer treatment market. The other key players existing in the market includes Novartis AG, Pfizer Inc., Eli Lilly and Company., Genentech Inc., Teva Pharmaceutical Industries Ltd., Merck & co., Inc., AstraZeneca, Bristol_ Myers Squibb Company, Eriochem SA., Laboratories IMA, Biotoscana group, Tuteur Argentina, and Celnova pharma among others.
Genentech, Inc. (a subsidiary of a subsidiary of F. Hoffmann-la Roche)
Genentech, Inc. was founded in 1976 and is headquartered in California, U.S. The company focuses on pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. The company offers range of product categories including Medicines & Products and Pipeline in which market focused category is Our Medicines & Products.
- In September 2021, Genentech presented data from industry-leading portfolio at esmo 2021 showing significant progress in early stage and uncommon cancers. This conference helped the company showcase its product portfolio in the conference which helped led to increased sales in the forecasted period.
The company has global presence in North-America.
Eli Lilly and Company
Eli Lilly and Company was founded in 1876 and is headquartered in Indiana, U.S. The company is engaged in production and trading of high quality medicines for which comes under the human pharmaceutical products. The company offers range of product categories such as Historic Medicines, Current Medicines in which market focused category is Current Medicines.
- In May 2020, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers. This new drug approval of the company has increased its sales and demand in the market leading to increased sales in the future.
The company has global presence in North America, Asia Pacific, South America, Europe, Latin America. The company has many subsidiaries such as Alnara Pharmaceuticals, Inc. (U.S.), AME Torreview LLC (U.S.), Andean Technical Operations Center (Peru), Dista-Produtos Quimicos & Farmaceuticos, LDA (Portugal) and E L Management LLC (U.S.) among others
Merck & Co., Inc.
Merck & Co., Inc. was founded in 1891 and is headquartered in Germany, Europe. The main focus of the company is that it delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It has following business segments such as Pharmaceuticals and Animal health segment. The market focused segment is Pharmaceuticals .The company offers product categories including Oncology, Vaccine, Hospital Acute Care, Immunology, Neuroscience, Virology, Cardiovascular, Diabetes, women's health in which the market focused category falls under Oncology.
For instance,
- In June 2020, Merck’s KEYTRUDA (pembrolizumab) approved in China for second-line treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma with tumors express PD-L1 (CPS ≥10).This helped the company to increase its product portfolio.
The company has global presence in the America, the Middle East, Africa, Eastern Europe and Asia Pacific. The company has many subsidiaries such as Abmaxis Inc., (Europe), Afferent Pharmaceuticals.Inc., (Europe), Aleis Pty Ltd (Europe), , Allflex (Argentina) , S.A.S. (France) ,Allflex Group (Europe), ,Allflex Private Limited (Europe) among others.
